Form 4: June Bray, Director at Quince Therapeutics, Acquires 27,000 Stock Options
SEC Form 4 Filing
Director June Bray acquired 27,000 employee stock options in Quince Therapeutics, Inc. on June 5, 2024.
Summary
- June Bray, a director at Quince Therapeutics, Inc. (QNCX), acquired 27,000 employee stock options on June 5, 2024.
- The exercise price of these options is $0.82.
- The options vest 100% on the one-year anniversary of the grant date, June 5, 2025.
- The options expire on June 5, 2034.
- Following the transaction, June Bray directly owns 27,000 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to a director, which doesn't inherently indicate positive or negative news.
Positives
- A director's acquisition of stock options can be seen as a positive signal, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- Shareholders may view this as a sign of confidence from a company director.
Key Dates
| Date | Description |
|---|---|
| 06/05/2024 | Date of transaction: June Bray acquired 27,000 employee stock options. |
| 06/05/2025 | Vesting date: 100% of the shares subject to the stock option will vest. |
| 06/05/2034 | Expiration date: The stock options expire. |
| 06/07/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.